CIDP: Improving Timely Diagnosis, Assessment, and Treatment

Released On
August 5, 2021

Expires On
August 5, 2022

Media Type
Internet

Completion Time
60 minutes

Specialty
Neurology, Neuromuscular Specialists, Immunology, Primary Care

Topic(s)
CIDP

Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, working in collaboration with the GBS|CIDP Foundation International.


Supported by an educational grants from argenx US, Inc. and Grifols.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

The educational design of this activity addresses the needs of neurologists, neuromuscular specialists, immunologists, primary care providers, hospitalists, emergency physicians, advanced practitioners, nurses, and pharmacists involved in the treatment of patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).

Statement of Need/Program Overview

While CIDP is the most common of the acquired immune-mediated demyelinating neuropathies, it remains a challenge to differentiate it from other immune-mediated inflammatory conditions. Clinicians may also find it difficult to recognize atypical presentations of CIDP. These issues lead to delayed diagnoses, misdiagnoses, and missed opportunities for early and timely interventions.

Join experts in the management of CIDP for a comprehensive review of the symptoms and clinical features of CIDP, along with practical and successful strategies to improve diagnosis and disease assessment. The safety, efficacy, and tolerability of available treatment options will also be explored, and strategies to address barriers to optimal management and emerging concepts in disease pathophysiology that could provide new targeted options to more effectively manage CIDP will be addressed.

Because of the significant morbidity and disease burden associated with CIDP, it is critical that clinicians and their patients be on the same page in terms of diagnosis, treatment expectations, and maintenance therapy to maximize outcomes. Direct your patients with CIDP to the associated patient activity, “Becoming Empowered with CIDP: Making My Voice Heard” at NeuroCareLive.com. Patients and their caregivers will become more familiar with both current and emerging management approaches, while recognizing their role in the treatment and monitoring process.

Educational Objectives

Upon completion of this activity, participants should be able to:

  • Formulate a differential-diagnosis strategy for a patient presenting with symptoms suggestive of CIDP
  • Identify a treatment plan using current therapeutic options, including coordination of multidisciplinary care and provision of supportive treatment
  • Summarize data from ongoing clinical trials with agents targeting the IgG neonatal Fc receptor

Faculty

Peter D. Donofrio, MD

Professor of Neurology
Vanderbilt University Medical Center

Betsy Blake, PharmD, BCPS, FNAP

Clinical Associate Professor
Director of Interprofessional Education
University of South Carolina College of Pharmacy

Pysician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Peter D. Donofrio, MD

  • Consulting Fee (e.g., Advisory Board): argenx US, Inc.

Betsy Blake, PharmD, BCPS, FNAP: Nothing to disclose

The planners and managers have the following relevant financial relationships with ineligible companies:

Lindsay Borvansky: Nothing to disclose.
Andrea Funk: Nothing to disclose.
Liddy Knight: Nothing to disclose.
Ashley Cann: Nothing to disclose.
Carole Drexel: Nothing to disclose.
Jaimee Harris-Gold: Nothing to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC. do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Method of Participation

There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.

Hardware/Software Requirements

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information

Accreditation Support:
Please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Technical Support:
For any technical issues or issues with your CME Certificate, please contact NeuroSeriesLive at 877-394-1306 or at Support@NeuroSeriesLive.com.

PlatformQ Health Privacy Policy:

By clicking “Start Activity” you are agreeing to PlatformQ Health’s privacy policy. PlatformQ Health takes your privacy very seriously. The full Privacy Policy found here describes (i) the types of information we collect from you when you visit our Site; (ii) how we use the information we collect; (iii) with whom and why we share it; and (iv) the choices we offer regarding our use of the information. We also describe how to contact us about our privacy practices.

Information we collect is primarily used to communicate with program participants, award CME/CE credits, manage user accounts, recommend relevant programs and perform data analysis to inform educational outcomes.

In plain English, here is what we affirm:

  • You can change your registration profile at any time from our “Profile” page
  • To request any of these changes without logging in, please call us at 1 (877) 394-1306 or email us at support@PlatformQHealth.com
  • You can end your association with PlatformQ Health at any time
  • PlatformQ Health does not spam, nor we do we rent or sell our email list in whole or in part. Any program-related data sharing is for engagement verification and opt-in based further education
  • EU citizens can request a complete record of their account and/or request to have their personal data expunged by contacting support@PlatformQHealth.com with the subject line “Data Request”

You acknowledge and agree that by beginning this activity, you have affirmatively agreed to this Privacy Policy and consented to receiving electronic messages in conformance with this Privacy Policy. Please read the full privacy policy located at: www.platformqhealth.com/privacy-policy/